{
  "id": 20634068,
  "title": "Dual-targeted CAR T-cell therapy shows promise in patients with treatment-resistant multiple myeloma",
  "url": "https://urgent.news/2026/11/18/dual-targeted-car-t-cell-therapy-shows-promise-in-patients-with",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T17:40:05.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-dual-car-cell-therapy-patients.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "A first-in-human study by Mass General Brigham Cancer Institute investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. TriPRIL—short for trimeric APRIL (a proliferation-inducing ligand)—recognizes two proteins on myeloma cells instead of just one. Researchers…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}